Nifty 50Healthcarenifty 50
Dr. Reddy's Laboratories Share Price & Analysis
Dr. Reddy's is a global pharmaceutical company with strengths in generics, biosimilars, and proprietary products.
Live price
DRREDDY · Healthcare
₹1,310.00
−0.90 (−0.07%)
Day High
₹1,323.70
Day Low
₹1,299.40
52W High
₹1,414.90
52W Low
₹1,101.00
Volume today: 22.00 L
Key fundamentals
Market cap
₹1.0 L Cr
P/E ratio
18.0x
P/B ratio
3.2x
ROE
15.5%
Debt / Equity
—
Dividend yield
0.7%
Revenue growth
—
Earnings growth
—
Live fundamentals from Yahoo Finance where available. Reference ratios may lag the latest quarterly results.
PaisaTamil Consensus
HOLDScore 61/100 · Medium confidence
Mixed signals across valuation and momentum. Existing investors may hold; new entries should wait for clarity.
12M Price Target
₹1,441
Low ₹1,284 · High ₹1,638
Analyst-style Breakdown
Strong Buy
0
Buy
2
Hold
20
Sell
0
Strong Sell
0
Derived from public market signals — price momentum, earnings trend, valuation, quality, and technical position — modelled in an analyst-style consensus format.
Signal Breakdown
Price Momentum65/100
1M +7.3%, 1Y +2.6%
Earnings Trend25/100
Latest quarter revenue ₹8.7k Cr, profit ₹925 Cr
Valuation85/100
P/E 18.0x vs sector median ~35x
Financial Quality78/100
ROE 15.5%, ROCE 14.0%
Technical Position65/100
Trading between 52W low 1101 and high 1415
Modelled from public market signals — not live broker analyst data. For education only; not SEBI-registered investment advice.
Price Chart
Quarterly Results
| Quarter | Revenue | Net Profit | EPS | Rev YoY | Profit YoY |
|---|---|---|---|---|---|
| Sept 2026 | ₹8.7k Cr | ₹925 Cr | ₹11.11 | -1.5% | -35.6% |
| Jun 2026 | ₹8.1k Cr | ₹444 Cr | ₹5.32 | — | — |
| Mar 2026 | ₹7.5k Cr | ₹221 Cr | ₹2.65 | — | — |
| Dec 2025 | ₹8.7k Cr | ₹1.2k Cr | ₹14.53 | — | — |
| Sept 2025 | ₹8.8k Cr | ₹1.4k Cr | ₹0.00 | — | — |
Reference Ratios
Market Capⓘ
₹1.0 L Cr
P/E Ratioⓘ
18.0x
P/B Ratioⓘ
3.2x
ROEⓘ
15.5%
ROCEⓘ
14.0%
Div Yieldⓘ
0.7%
Company Overview
Dr. Reddy's sells generics in US, India, Russia, and other markets. It has a growing biosimilar and nutraceutical portfolio.
Strengths
- + Diversified geographic revenue
- + Biosimilar pipeline potential
- + India branded generics growth
- + Strong balance sheet
Risks
- − US generics pricing pressure
- − Russia/CIS geopolitical exposure
- − R&D spend on biosimilars
- − Key product patent cliffs
Latest News
No recent news articles for Dr. Reddy's Laboratories yet. Check back after the next hourly scan.
Browse all market news →Investor Questions
Yes. Dr. Reddy's Laboratories is a current constituent of the Nifty 50, which means it is among the 50 largest and most liquid stocks on the National Stock Exchange (NSE).